These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35993234)

  • 21. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy is an effective treatment for high-risk T1-bladder cancer.
    Rödel C; Dunst J; Grabenbauer GG; Kühn R; Papadopoulos T; Schrott KM; Sauer R
    Strahlenther Onkol; 2001 Feb; 177(2):82-8; discussion 89. PubMed ID: 11233839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder.
    Ibrahim SM; Abd El-Hafeez ZM; Mohamed EM; Elsharawy IA; Kamal KM
    J Egypt Natl Canc Inst; 2007 Mar; 19(1):77-86. PubMed ID: 18839038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up.
    Thomas DJ; Roberts JT; Hall RR; Reading J
    BJU Int; 1999 Mar; 83(4):432-7. PubMed ID: 10210567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bladder preservation by chemoradiotherapy in combination with radical TUR-Bt in muscle invasive bladder cancer].
    Ishioka J; Kageyama Y; Ichiyanagi N; Saito Y; Nozu S; Nishida K; Fukuda H; Higashi Y
    Nihon Hinyokika Gakkai Zasshi; 2007 Sep; 98(6):752-6. PubMed ID: 17929456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
    Shipley WU; Kaufman DS; Zehr E; Heney NM; Lane SC; Thakral HK; Althausen AF; Zietman AL
    Urology; 2002 Jul; 60(1):62-7; discussion 67-8. PubMed ID: 12100923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study.
    Einstein AB; Wolf M; Halliday KR; Miller GJ; Hafermann M; Lowe BA; Meyers FJ; Leimert JT; Crawford ED
    Urology; 1996 May; 47(5):652-7. PubMed ID: 8650861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
    Zapatero A; Martin de Vidales C; Arellano R; Bocardo G; Pérez M; Ríos P
    Urol Oncol; 2010; 28(4):368-74. PubMed ID: 19362865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoradiation for organ preservation in the treatment of muscle invasive bladder cancer: Our Institutional Experience.
    Gupta S; De S; Leekha N; Sahay SC; Chaudary P; Srinivasan S; Nandy M
    Gulf J Oncolog; 2016 Sep; 1(22):55-60. PubMed ID: 28191808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.
    Akçetin Z; Todorov J; Tüzel E; Engehausen DG; Krause FS; Sauer R; Schrott KM; Rödel C
    Anticancer Res; 2005; 25(3A):1623-8. PubMed ID: 16033071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
    Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
    Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
    Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment?
    Pos F; Horenblas S; Dom P; Moonen L; Bartelink H
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):678-86. PubMed ID: 15708245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192.
    Wijnmaalen A; Helle PA; Koper PC; Jansen PP; Hanssens PE; Boeken Kruger CG; van Putten WL
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1043-52. PubMed ID: 9392543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.